Live Breaking News & Updates on Accelerated Assessment
Stay updated with breaking news from Accelerated assessment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The European Commission authorises the Comirnaty XBB.1.5-adapted Covid-19 vaccine, developed by BioNTech-Pfizer. It is the "third adaptation of this vaccine to respond to new Covid-19 variants". This has been announced earlier today by the EU Commission in a statement. The vaccine is "authorised for adults, children ....
With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therapies. PETACH TIKVAH, Israel, Nov. 9, 2022 /PRNewswire/ Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of South and Central America and the Caribbean markets ("Latin America") to its multi-territorial agreement with Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. "The expansion of our partnership with Immunocore into LATAM is a significant milesto ....
With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therapies. PETACH TIKVAH, Israel, Nov. 9, 2022 /PRNewswire/ Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of South and Central America and the Caribbean markets ("Latin America") to its multi-territorial agreement with Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. "The expansion of our partnership with Immunocore into LATAM is a significant milesto ....
Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America - read this article along with other careers information, tips and advice on BioSpace ....